{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:20:48Z","timestamp":1788168048774,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00108-026-02174-6","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T08:33:10Z","timestamp":1787214790000},"page":"985-999","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiresistenz und neue Antiinfektiva","Multidrug resistance and new anti-infective agents"],"prefix":"10.1007","volume":"67","author":[{"given":"Katja","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J. G. T.","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"Gatermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Grabein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Rademacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias W.","family":"Pletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"2174_CR1","unstructured":"Deutsche Gesellschaft f\u00fcr Hygiene und Mikrobiologie e.\u202fV. (DGHM) (Hrsg) (2025) S3-Leitlinie: Antibiotikatherapie schwerer Infektionen mit multiresistenten Bakterien - MERTher. Langversion, 1.0. AWMF-Registernummer 067-011."},{"key":"2174_CR2","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","volume":"404","author":"Antimicrobial Resistance Collaborators","year":"2024","unstructured":"Antimicrobial Resistance Collaborators (2024) Global burden of bacterial antimicrobial resistance 1990-2021: a\u00a0systematic analysis with forecasts to 2050. Lancet 404:1199\u20131226","journal-title":"Lancet"},{"key":"2174_CR3","doi-asserted-by":"crossref","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA (2024) Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis","DOI":"10.1093\/cid\/ciae403"},{"key":"2174_CR4","doi-asserted-by":"crossref","unstructured":"Vrancianu CO, Gheorghe I, Dobre EG, Barbu IC, Cristian RE, Popa M, Lee SH, Limban C, Vlad IM, Chifiriuc MC (2020) Emerging Strategies to Combat \u03b2\u2011Lactamase Producing ESKAPE Pathogens. Int J Mol Sci\u00a021.","DOI":"10.3390\/ijms21228527"},{"key":"2174_CR5","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJM200003093421007","volume":"342","author":"BE Murray","year":"2000","unstructured":"Murray\u00a0BE (2000) Vancomycin-resistant enterococcal infections. N Engl J Med 342:710\u2013721","journal-title":"N Engl J Med"},{"key":"2174_CR6","first-page":"3","volume":"28","author":"MABJ Fischer","year":"2023","unstructured":"Fischer\u00a0MABJ, Kriebel\u00a0N, Weber\u00a0RE, Wohlfarth\u00a0E, Maechler\u00a0F, Noll\u00a0I, Abu Sin\u00a0M, Werner\u00a0G (2023) Eigenschaften, H\u00e4ufigkeit und Verbreitung von Vancomycin-resistenten Enterokokken in Deutschland \u2013 Update. Epid Bull 28:3\u201317","journal-title":"Epid Bull"},{"key":"2174_CR7","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s15010-024-02423-6","volume":"53","author":"G Tiseo","year":"2025","unstructured":"Tiseo\u00a0G, Galfo\u00a0V, Carbonara\u00a0S, Marino\u00a0A, Di Caprio\u00a0G, Carretta\u00a0A, Mularoni\u00a0A, Mariani\u00a0MF, Maraolo\u00a0AE, Scotto\u00a0R, Dalfino\u00a0L, Corbo\u00a0L, Macera\u00a0M, Medaglia\u00a0AA, d\u2019Errico\u00a0ML, Gio\u00e8\u00a0C, Sgroi\u00a0C, Del Vecchio\u00a0RF, Ceccarelli\u00a0G, Albanese\u00a0A, Buscemi\u00a0C, Talamanca\u00a0S, Foti\u00a0G, De Stefano\u00a0G, Franco\u00a0A, Iacobello\u00a0C, Corrao\u00a0S, Morana\u00a0D, Pieralli\u00a0F, Gentile\u00a0I, Santantonio\u00a0T, Cascio\u00a0A, Coppola\u00a0N, Cacopardo\u00a0B, Venditti\u00a0M, Menichetti\u00a0F, Falcone\u00a0M (2025) Bacteremic nosocomial pneumonia caused by Gram-negative bacilli: results from the nationwide ALARICO study in Italy. Infection 53:1041\u20131050","journal-title":"Infection"},{"key":"2174_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126479","volume":"10","author":"C Stein","year":"2015","unstructured":"Stein\u00a0C, Makarewicz\u00a0O, Bohnert\u00a0JA, Pfeifer\u00a0Y, Kesselmeier\u00a0M, Hagel\u00a0S, Pletz\u00a0MW (2015) Three Dimensional Checkerboard Synergy Analysis of Colistin, Meropenem, Tigecycline against Multidrug-Resistant Clinical Klebsiella pneumonia Isolates. PLoS One 10:e0126479","journal-title":"PLoS One"},{"issue":"20\/21","key":"2174_CR9","first-page":"3","volume":"2025","author":"NMS Pfennigwerth","year":"2025","unstructured":"Pfennigwerth\u00a0NMS, Pankok\u00a0EJ, Gatermann\u00a0F, Gatermann\u00a0SG (2025) Bericht des Nationalen Referenzzentrums f\u00fcr gramnegative Krankenhauserreger f\u00fcr das Jahr 2024. Epid Bull 2025(20\/21):3\u201311","journal-title":"Epid Bull"},{"key":"2174_CR10","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/cid\/ciad725","volume":"78","author":"M Falcone","year":"2024","unstructured":"Falcone\u00a0M, Giordano\u00a0C, Leonildi\u00a0A, Galfo\u00a0V, Lepore\u00a0A, Suardi\u00a0LR, Riccardi\u00a0N, Barnini\u00a0S, Tiseo\u00a0G (2024) Clinical Features and Outcomes of Infections Caused by Metallo-\u03b2-Lactamase-Producing Enterobacterales: A 3\u2011Year Prospective Study From an Endemic Area. Clin Infect Dis 78:1111\u20131119","journal-title":"Clin Infect Dis"},{"key":"2174_CR11","doi-asserted-by":"crossref","unstructured":"Sandfort M, Hans JB, Fischer MA, Reichert F, Cremanns M, Eisfeld J, Pfeifer Y, Heck A, Eckmanns T, Werner G, Gatermann S, Haller S, Pfennigwerth N (2022) Increase in NDM\u20111 and NDM-1\/OXA-48-producing Klebsiella pneumoniae in Germany associated with the war in Ukraine, 2022. Euro Surveill\u00a027","DOI":"10.2807\/1560-7917.ES.2022.27.50.2200926"},{"key":"2174_CR12","doi-asserted-by":"publisher","unstructured":"Rober Koch Institut (2025) Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2023. https:\/\/doi.org\/10.25646\/13043","DOI":"10.25646\/13043"},{"issue":"35","key":"2174_CR13","first-page":"3","volume":"2024","author":"KHJ Gr\u00f6schner","year":"2024","unstructured":"Gr\u00f6schner\u00a0KHJ, Abu Sin\u00a0M, Pantke\u00a0E, Lilienthal\u00a0N, Stommel\u00a0B, Eckmanns\u00a0T (2024) Gesetzliche Verpflichtungen des RKI und BfArM im Rahmen der Einstufung von Reserveantibiotika. Epid Bull 2024(35):3\u20138","journal-title":"Epid Bull"},{"key":"2174_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0140-6736(24)02081-6","volume":"405","author":"N Macesic","year":"2025","unstructured":"Macesic\u00a0N, Uhlemann\u00a0AC, Peleg\u00a0AY (2025) Multidrug-resistant Gram-negative bacterial infections. Lancet 405:257\u2013272","journal-title":"Lancet"},{"key":"2174_CR15","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1055\/a-2541-9872","volume":"79","author":"J Rademacher","year":"2025","unstructured":"Rademacher\u00a0J, Ewig\u00a0S, Grabein\u00a0B, Nachtigall\u00a0I, Abele-Horn\u00a0M, Deja\u00a0M, Ga\u00dfner\u00a0M, Gatermann\u00a0S, Geffers\u00a0C, Gerlach\u00a0H, Hagel\u00a0S, Heu\u00dfel\u00a0CP, Kluge\u00a0S, Kolditz\u00a0M, Kramme\u00a0E, K\u00fchl\u00a0H, Panning\u00a0M, Rath\u00a0PM, Rohde\u00a0G, Schaaf\u00a0B, Salzer\u00a0HJF, Schreiter\u00a0D, Schweisfurth\u00a0H, Unverzagt\u00a0S, Weigand\u00a0MA, Welte\u00a0T, Pletz\u00a0MW (2025) Epidemiology, diagnosis and treatment of adult patients with nosocomial pneumonia. Pneumologie 79:e3\u2013e57","journal-title":"Pneumologie"},{"key":"2174_CR16","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1093\/jac\/dkaf376","volume":"80","author":"SE M\u00fcller","year":"2025","unstructured":"M\u00fcller\u00a0SE, Junker\u00a0S, Rehner\u00a0J, F\u00f6rster\u00a0M, Keller\u00a0A, Molano\u00a0LG, Becker\u00a0SL (2025) Comparative in vitro activity of ceftazidime-avibactam plus aztreonam and the fixed combination aztreonam\/avibactam against multidrug-resistant Pseudomonas aeruginosa. J\u00a0Antimicrob Chemother 80:3352\u20133356","journal-title":"J Antimicrob Chemother"},{"key":"2174_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.01.012","volume":"88","author":"L Onorato","year":"2024","unstructured":"Onorato\u00a0L, de Luca\u00a0I, Monari\u00a0C, Coppola\u00a0N (2024) Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis. J\u00a0Infect 88:106113","journal-title":"J Infect"},{"key":"2174_CR18","doi-asserted-by":"crossref","unstructured":"Risco-Risco C, Henriquez-Camacho C, Herrera-Rueda M, Barber\u00e1n J, Andaluz-Ojeda D (2024) Cefiderocol Versus Best Available Therapy in the Treatment of Critically Ill Patients with Severe Infections Due to Resistant Gram-Negative Bacteria: A\u00a0Systematic Review and Meta-Analysis. Antibiotics (Basel) 13","DOI":"10.3390\/antibiotics13111048"},{"key":"2174_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaa114","volume":"3","author":"NM Brown","year":"2021","unstructured":"Brown\u00a0NM, Goodman\u00a0AL, Horner\u00a0C, Jenkins\u00a0A, Brown\u00a0EM (2021) Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK. JAC Antimicrob Resist 3:dlaa114","journal-title":"JAC Antimicrob Resist"},{"key":"2174_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/cid\/cir034","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu\u00a0C, Bayer\u00a0A, Cosgrove\u00a0SE, Daum\u00a0RS, Fridkin\u00a0SK, Gorwitz\u00a0RJ, Kaplan\u00a0SL, Karchmer\u00a0AW, Levine\u00a0DP, Murray\u00a0BE, M\u00a0JR, Talan\u00a0DA, Chambers\u00a0HF (2011) Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52:285\u2013292","journal-title":"Clin Infect Dis"},{"key":"2174_CR21","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/bcp.15671","volume":"89","author":"M Samura","year":"2023","unstructured":"Samura\u00a0M, Takada\u00a0K, Hirose\u00a0N, Kurata\u00a0T, Nagumo\u00a0F, Uchida\u00a0M, Inoue\u00a0J, Tanikawa\u00a0K, Enoki\u00a0Y, Taguchi\u00a0K, Matsumoto\u00a0K, Ueda\u00a0T, Fujimura\u00a0S, Mikamo\u00a0H, Takesue\u00a0Y, Mitsutake\u00a0K (2023) Comparison of the efficacy and safety of standard- and high-dose daptomycin: A systematic review and meta-analysis. Br J Clin Pharmacol 89:1291\u20131303","journal-title":"Br J Clin Pharmacol"},{"key":"2174_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/phar.2070","volume":"38","author":"TT Timbrook","year":"2018","unstructured":"Timbrook\u00a0TT, Caffrey\u00a0AR, Luther\u00a0MK, Lopes\u00a0V, LaPlante\u00a0KL (2018) Association of Higher Daptomycin Dose (7\u202fmg\/kg or Greater) with Improved Survival in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia. Pharmacotherapy 38:189\u2013196","journal-title":"Pharmacotherapy"},{"key":"2174_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jgar.2019.10.008","volume":"21","author":"C Shi","year":"2020","unstructured":"Shi\u00a0C, Jin\u00a0W, Xie\u00a0Y, Zhou\u00a0D, Xu\u00a0S, Li\u00a0Q, Lin\u00a0N (2020) Efficacy and safety of daptomycin versus linezolid treatment in patients with vancomycin-resistant enterococcal bacteraemia: An updated systematic review and meta-analysis. J\u00a0Glob Antimicrob Resist 21:235\u2013245","journal-title":"J Glob Antimicrob Resist"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02174-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02174-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02174-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T08:49:06Z","timestamp":1788166146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-026-02174-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2174"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02174-6","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"22 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Schneider\n                      : A.\u00a0Finanzielle Interessen: AstraZeneca (Vortragshonorar). \u2013\u00a0B. Nichtfinanzielle Interessen: Angestellte Fach\u00e4rztin f\u00fcr Innere Medizin, Institut f\u00fcr Infektionsmedizin und Krankenhaushygiene, Universit\u00e4tsklinikum Jena, Friedrich-Schiller-Universit\u00e4t Jena |\u00a0\u2013 Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Innere Medizin (DGIM), Deutsche Gesellschaft f\u00fcr Infektiologie (DGI).\n                      M.J.G.T.\u00a0Vehreschild\n                      : A.\u00a0Finanzielle Interessen: Zahlung an die Institution: MSD, Heel, Roche, Tillotts, Pfizer. \u2013\u00a0Zahlung an die Person: Akademisches Forum Augsburg, Akademie f\u00fcr Infektionsmedizin, AstraZeneca, bioM\u00e9rieux, Biotest, DGI, European Society of Neurogastroenterology, Falk Foundation, FomF GmbH, GFO Kliniken Bonn, GILEAD, GSK, Helios Kliniken, Hessisches Landessozialgericht, Infektio-Forum, Janssen-Cilag GmbH, Klinik Bavaria Kreischa, Klinikum Kassel, Klinikverbund St. Antonius & St. Josef GmbH, Landes\u00e4rztekammer Hessen, LMU Kliniken, MRE Netzwerk F\u00f6rderverein, MSD, Pfizer, Shionogi, Streamed up, St.\u00a0Vincent Hospital, Tillotts, Vivantes |\u00a0\u2013 Zahlung an die Person: GILEAD, Tillotts, Pfizer, Bioaster, GSK, Ecraid, EUMEDICA, Bactolife, PAION | \u2013\u00a0B. Nichtfinanzielle Interessen: Medizinische Klinik 2, Infektiologie, Universit\u00e4tsklinikum Frankfurt, Goethe-Universit\u00e4t Frankfurt | Vorstandsvorsitzende der DGI.\n                      J.\u00a0Rademacher\n                      : A.\u00a0Finanzielle Interessen: Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Pfizer, InfectoPharm, Shionogi.\u00a0\u2013 Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u202f\u00c4.: InfectoPharm. \u2013\u00a0B. Nichtfinanzielle Interessen: Praxisinhaberin Praxis f\u00fcr Pneumologie und Infektiologie Hamburg, Klinik f\u00fcr Pneumologie und Infektiologie, Medizinische Hochschule Hannover | Vorstand CAPNETZ, PROGNOSIS | Gr\u00fcnderin PneumoPearls.\n                      M.\u00a0Pletz\n                      : A.\u00a0Finanzielle Interessen: Pfizer\u00a0\u2013 klinische Studie zur Krankheitslast der ambulant erworbenen Pneumonie. \u2013\u00a0Pfizer, MSD, Shionogi, GSK, bioM\u00e9rieux, InfectoPharm (Podcast), Moderna, BioNTech, Novartis.\u00a0\u2013 Berater: Pfizer, MSD, Shionogi, GSK, bioM\u00e9rieux, InfectoPharm (Podcast), Moderna, BioNTech, Novartis, Tillotts. \u2013\u00a0B. Nichtfinanzielle Interessen: Universit\u00e4tsklinikum Jena, Institut f\u00fcr Infektionsmedizin und Krankenhaushygiene, Friedrich-Schiller-Universit\u00e4t Jena | Vorstand: DGI, Deutsche Sepsis-Gesellschaft (DSG), CAPNETZ, Paul-Ehrlich-Gesellschaft f\u00fcr Infektionstherapie (PEG) | Surviving Sepsis Campaign: German Delegate | Leitlinien: S3-Leitlinie ambulant erworbene Pneumonie, S3-Leitlinie nosokomial erworbene Pneumonie, S3-Leitlinie Sepsis, S2k-Leitlinie PEG, S2-Leitlinie Post-COVID, S3-Leitlinie \u201eAntibiotikatherapie schwerer Infektionen mit multiresistenten Bakterien\u201c.\n                      S.\u00a0Hagel\n                      : A.\u00a0Finanzielle Interessen: Shionogi, Pfizer, MSD, Advanz, InfectoPharm jeweils Vortragshonorar.\u00a0\u2013 B. Nichtfinanzielle Interessen: Angestellter Arzt, Institut f\u00fcr Infektionsmedizin und Krankenhaushygiene, Universit\u00e4tsklinikum Jena, Friedrich-Schiller-Universit\u00e4t Jena.\n                      S.\u00a0Gatermann\n                      : A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Mittel f\u00fcr Entwicklung der S3-Leitlinie \u201eAntibiotikatherapie schwerer Infektionen mit multiresistenten Bakterien\u201c F\u00f6rderkennzeichen 01VSF22010 (Gemeinsamer Bundesausschuss [G-BA]). \u2013\u00a0B. Nichtfinanzielle Interessen: Universit\u00e4tsprofessor C4, Medizinische Mikrobiologie, Ruhr-Universit\u00e4t Bochum | \u00c4rztlicher Leiter Institut f\u00fcr Medizinische Laboratoriumsdiagnostik (IML) Bochum GmbH | Gesellschafter IML Bochum GmbH | Vorsitzender des deutschen Nationalen Antibiotika-Sensitivit\u00e4tstest-Komitees (NAK) sowie des European Committee on Antimicrobial Susceptibility Testing (EUCAST).\n                      B.\u00a0Grabein\n                      : A.\u00a0Finanzielle Interessen: Vortragshonorare von Advanz, Berlin-Chemie, Biotest, Gilead, MSD, PAION, Pfizer, Shionogi | Kostenerstattung von Pfizer, InfectoPharm, Tillotts.\u00a0\u2013 B. Nichtfinanzielle Interessen: Leitende \u00c4rztin der Stabsstelle Klinische Mikrobiologie und Krankenhaushygiene am LMU Klinikum M\u00fcnchen | Mitgliedschaft in folgenden Fachgesellschaften: Paul-Ehrlich-Gesellschaft f\u00fcr Infektionstherapie e.\u202fV. (Vorstandsmitglied), Deutsche Gesellschaft f\u00fcr Hygiene und Mikrobiologie (DGHM), DGI, Deutschsprachige Mykologische Gesellschaft (DMykG), Deutsche Sepsis-Gesellschaft (DSG), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (Fellow).","order":2,"name":"Ethics","label":"Autorinnen und Autoren","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":3,"name":"Ethics","label":"Wissenschaftliche Leitung","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","label":"Der Verlag","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}